6533b7d5fe1ef96bd126432b
RESEARCH PRODUCT
Study on the Linezolid Prescription According to the Approval of Indication in a University Hospital.
Pérez-cebrián ManuelaSuárez-varela María M MoralesFont-noguera IsabelMonte-boquet EmilioPoveda-andrés Jose LuísMartín-moreno Jose MaríaRubio-lópez NuriaRuiz-rojo EliasLlopis-gonzález Agustínsubject
University hospitalDrug safety evaluationLinezolid prescriptionApproval of indicationsOriginal ArticleDrug-related problemsdescription
Indications for linezolid use are nosocomial or community-acquired pneumonia and skin infections or soft tissue infection caused by gram-positive microorganisms, but new recommendations may emerge. It is important to balance benefits with risks because severe adverse events have been described in patients taking linezolid treatment. Accordingly, we evaluated the suitability of linezolid prescription according to approval of indication by evaluating the presence of drug-related problems (DRP) in a University hospital. DRP were identified in 36 patients (50.0%). In most cases, they were related to known or established indications (15 patients, 20.8%), to safety (5 patients, 6.9%), and to both in others (16 patients, 22.2%). No DRP were recorded, which modified linezolid efficacy. DRP were significantly higher in the patients treated by an approved indication in Spain (63.3%) than in those treated by an unapproved indication in Spain (28.6%). We concluded that new studies about extending linezolid indications may be necessary.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-09-03 | Iranian journal of pharmaceutical research : IJPR |